<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ACTG1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ACTG1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Actin Gamma 1 (Cytoplasmic)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>72</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000184009</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P63261</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>102560</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>4.8 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>6</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>1.2 kb</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Gamma-Actin</td>
</tr>
<tr>
<td class="label">Dendritic Spine</td>
<td>High in spine heads</td>
</tr>
<tr>
<td class="label">Postsynaptic Density</td>
<td>Enriched</td>
</tr>
<tr>
<td class="label">Growth Cones</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Axon Initial Segment</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Synaptic Vesicles</td>
<td>Associated</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Gamma-Actin Stabilizers</td>
<td>Protect spine actin in AD</td>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ACTG1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ACTG1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Actin Gamma 1 (Cytoplasmic)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q25.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>72</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000184009</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P63261</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>102560</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>4.8 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>6</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>1.2 kb</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Gamma-Actin</td>
</tr>
<tr>
<td class="label">Dendritic Spine</td>
<td>High in spine heads</td>
</tr>
<tr>
<td class="label">Postsynaptic Density</td>
<td>Enriched</td>
</tr>
<tr>
<td class="label">Growth Cones</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Axon Initial Segment</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Synaptic Vesicles</td>
<td>Associated</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Gamma-Actin Stabilizers</td>
<td>Protect spine actin in AD</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Restore gamma-actin expression</td>
</tr>
<tr>
<td class="label">AMPA Receptor Modulators</td>
<td>Compensate for trafficking defects</td>
</tr>
<tr>
<td class="label">Actin-Polymerization Enhancers</td>
<td>Promote spine growth</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cochlea</td>
<td>High</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Description</td>
</tr>
<tr>
<td class="label">ACTG1 Knockout</td>
<td>Global deletion</td>
</tr>
<tr>
<td class="label">Conditional KO</td>
<td>Neuron-specific</td>
</tr>
<tr>
<td class="label">Heterozygous KO</td>
<td>Partial loss</td>
</tr>
<tr>
<td class="label">AD Cross</td>
<td>APP/PS1/ACTG1 KD</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Stage</td>
</tr>
<tr>
<td class="label">γ-Actin Stabilizers</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Research</td>
</tr>
<tr>
<td class="label">AMPA Modulators</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">Polymerization Enhancers</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/huntington" style="color:#ef9a9a">Huntington</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">50 edges</a></td>
</tr>
</table>
ACTG1 encodes gamma-actin 1, a cytoplasmic actin isoform highly expressed in neuronal cells and inner ear hair cells. Together with beta-actin, gamma-actin forms the actin cytoskeleton essential for cell structure, motility, and intracellular transport. In the nervous system, gamma-actin is enriched in dendritic spines and synaptic terminals, where it regulates synaptic plasticity, receptor trafficking, and neurotransmitter release. Gamma-actin is particularly important for maintaining spine stability and postsynaptic density organization[@baines2009][@schevzov2012].
Mutations in ACTG1 cause Baraitser-Winter syndrome (BRWS), a neurodevelopmental disorder that shares features with ACTB-related BRWS, including brain malformations, intellectual disability, and sensorineural hearing loss. Additionally, gamma-actin dysfunction contributes to age-related cognitive decline and accelerates pathology in Alzheimer's disease (AD) models, highlighting its importance in both development and neurodegeneration[@riviere2012][@li2023].
Gamma-actin shares 99% amino acid identity with beta-actin, with most differences concentrated in the N-terminal region:
The subtle structural differences confer functional specificity through isoform-specific interactions with binding proteins.
Gamma-actin shows distinct localization and function compared to beta-actin:
This differential distribution suggests specialized roles in synaptic function[@minin2011][@mueller2011].
Gamma-actin contributes to:
Gamma-actin is required for both induction and maintenance of LTP:
The gamma-actin isoform plays a non-redundant role in memory consolidation[@vedula2019][@leonard2012].
Gamma-actin directly regulates AMPA receptor dynamics:
Gamma-actin maintains spine stability through:
Heterozygous de novo mutations in ACTG1 cause BRWS with features including:
Gamma-actin dysfunction contributes to AD pathogenesis:
Mouse models with neuronal gamma-actin knockdown show accelerated cognitive decline and enhanced amyloid plaque burden[@li2023].
In PD models, gamma-actin is affected by:
ALS-related changes include:
In the inner ear, gamma-actin is essential for:
Gamma-actin shows widespread but region-specific expression:
Gamma-actin interacts with neuronal-specific partners:
Key questions in gamma-actin research:
Gamma-actin as a clinical marker:
γ-actin-deficient mice display:
The following diagram shows the key molecular relationships involving ACTG1 Gene discovered through SciDEX knowledge graph analysis: